Regional thermochemotherapy versus hepatic arterial infusion chemotherapy for palliative treatment of advanced hilar cholangiocarcinoma: a retrospective controlled study

Chen, Yaoting; Li, Huiqing; Jiang, Xiongying; Chen, Dong; Ni, Jingxian; Sun, Hongzan; Luo, Jun; Yao, Herui; Xu, Li

doi:10.1007/s00330-016-4208-7

Cited by 3 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Median OS (11.5, 95% CI: 7.7, 14.3) in the DEB-TACE group was similar to those found in previous studies ( Kim et al, 2008 ; Zhou et al, 2020 ) but was longer than that of the C-TACE group in this study. Several studies of second-line chemotherapy for advanced biliary tract cancer showed that median OS was less than 8 months, and hepatic arterial infusion chemotherapy for advanced cholangiocarcinoma showed median OS was 13.2 months ( Chen et al, 2016 ; Lamarca et al, 2021 ; Huang et al, 2022 ). The OS of these studies are similar to ours (median OS in DEB-TACE group: 11.5 months).…”

Section: Discussionmentioning

confidence: 99%

DEB-TACE with irinotecan versus C-TACE for unresectable intrahepatic cholangiocarcinoma: a prospective clinical study

Wang

Yang

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Objectives: DEB-TACE with irinotecan and C-TACE were compared with regards to safety and efficacy for the therapy of intrahepatic cholangiocarcinoma (ICC).Methods: Institutional Review Board approved our trial and we registered it in the Chinese Clinical Trial Registry (ChiCTR1900022856). Forty patients with biopsy-confirmed ICC were randomised to either receive DEB-TACE or C-TACE treatment with 20 patients in each treatment arm. The primary endpoints objective response rate (ORR) and progression free survival (PFS) using the mRECIST to evaluate the tumours. The secondary endpoints were overall survival (OS) and safety. The chi-square was used to analyse the data. The Kaplan-Meier method and Cox analysis were used to evaluate the survival data.Results: ORR (70% in DEB-TACE group vs. 20% in C-TACE, p = .001) at 1 month after therapy, ORR (50% vs. 15%, p = .018) at 3 months and DCR (70% vs. 30%, p = .011) at 6 months, while no difference was found in other groups. (all p > .05) The median PFS with DEB-TACE was longer than that with C-TACE (8.0 months vs. 3.0 months) (p = .042). Although the median OS was longer with DEB-TACE than with C-TACE (11.5 months vs. 9.0 months), the difference was not statistically significant (p = .280). The Cox regression analysis demonstrated that TACE sessions (p = .017) and low CA125 levels (p = .001) were independent favourable prognostic factors. The most frequent adverse event was elevated transaminase levels (20/20 in DEB-TACE group vs. 15/20 in C-TACE group) (p = .047).Conclusion: Our prospective study suggested better ORR and PFS with DEB-TACE with irinotecan as compared to C-TACE with irinotecan in the treatment of unresectable ICC.

show abstract

Section: Discussionmentioning

confidence: 99%

DEB-TACE with irinotecan versus C-TACE for unresectable intrahepatic cholangiocarcinoma: a prospective clinical study

Wang

Yang

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…Regional hyperthermia, in comparison, does not require sedation and only takes 30-60 min. Common adverse events related to regional hyperthermia and mEHT during the procedure are thermal stress, local discomfort, hot sensation, abdominal and back pain, bolus pressure, position-related discomfort or pain, tachycardia, and grade I and II burns at the heated region[ 29 - 46 ]. Increased liver enzymes, skin rashes at the heated region, and occasional mild subcutaneous fat necrosis, nausea, dyspnea, and urinary urgency can also occur after the procedure[ 29 , 39 - 46 ].…”

Section: Hyperthermia In Cancer Treatmentmentioning

confidence: 99%

“…Common adverse events related to regional hyperthermia and mEHT during the procedure are thermal stress, local discomfort, hot sensation, abdominal and back pain, bolus pressure, position-related discomfort or pain, tachycardia, and grade I and II burns at the heated region[ 29 - 46 ]. Increased liver enzymes, skin rashes at the heated region, and occasional mild subcutaneous fat necrosis, nausea, dyspnea, and urinary urgency can also occur after the procedure[ 29 , 39 - 46 ]. Several studies have reported a higher incidence of hematotoxicity in patients treated with hyperthermia than in those without hyperthermia[ 30 , 31 , 47 ], possibly associated with the increased cytotoxicity of chemotherapeutic agents in hyperthermia[ 13 , 15 , 18 ].…”

Section: Hyperthermia In Cancer Treatmentmentioning

confidence: 99%

“…fewer tumor related symptoms) and laboratory results were reported in a detailed case report of a patient with unresectable hilar CCC[ 75 ]. Similarly, extending hepatic arterial infusion chemotherapy with hyperthermia in patients with advanced BC have resulted in longer progression-free and overall survival and in better disease control rate[ 45 , 46 ] (Figures 2 and 3 ). The positive effects of hyperthermia were observed after the first few treatments[ 46 ], complete responses have been reported[ 46 ], and no increased toxicity after chemotherapy occurred[ 45 ].…”

Section: Hyperthermia In Biliary Tract Cancersmentioning

confidence: 99%

See 1 more Smart Citation

Evidence based tools to improve efficiency of currently administered oncotherapies for tumors of the hepatopancreatobiliary system

Herold

Szász

Dank

2021

WJGO

View full text Add to dashboard Cite

Hepatopancreatobiliary tumors are challenging to treat, and the advanced or metastatic forms have a very low 5-year survival rate. Several drug combinations have been tested, and new therapeutic approaches have been introduced in the last decades, including radiofrequency and heat based methods. Hyperthermia is the artificial heating of tumors by various biophysical methods that may possess immunostimulant, tumoricidal, and chemoradiotherapy sensitizer effects. Both whole-body and regional hyperthermia studies have been conducted since the 1980s after the introduction of deep-seated tumor hyperthermia techniques. Results of the effects of hyperthermia in hepatocellular and pancreatic cancer are known from several studies. Hyperthermia in biliary cancers is a less investigated area. High local and overall responses to treatment, increased progression-free and overall survival, and improved laboratory and quality-of-life results are associated with hyperthermia in all three tumor types. With the evolution of chemotherapeutic agents and the introduction of newer techniques, the combination of adjuvant hyperthermia with those therapies is advantageous and has not been associated with an increase in alarming adverse effects. However, despite the many positive effects of hyperthermia, its use is still only known at the experimental level, and its concomitant utilization in routine cancer treatment is not certain because of the lack of thorough clinical studies.

show abstract

Hepatic arterial infusion chemotherapy following simultaneous metallic stent placement and iodine-125 seed strands for advanced cholangiocarcinoma causing malignant obstructive jaundice: a propensity score matching study

Shi

et al. 2021

Jpn J Radiol

View full text Add to dashboard Cite

Regional thermochemotherapy versus hepatic arterial infusion chemotherapy for palliative treatment of advanced hilar cholangiocarcinoma: a retrospective controlled study

Abstract: • Regional TCT is a novel combination for palliative treatment of advanced HC • Our data showed significantly promising outcomes in the TCT group • HC patients with metal stenting appeared to derive greater benefit from TCT.

Cited by 3 publications

References 33 publications

DEB-TACE with irinotecan versus C-TACE for unresectable intrahepatic cholangiocarcinoma: a prospective clinical study

DEB-TACE with irinotecan versus C-TACE for unresectable intrahepatic cholangiocarcinoma: a prospective clinical study

Evidence based tools to improve efficiency of currently administered oncotherapies for tumors of the hepatopancreatobiliary system

Hepatic arterial infusion chemotherapy following simultaneous metallic stent placement and iodine-125 seed strands for advanced cholangiocarcinoma causing malignant obstructive jaundice: a propensity score matching study

Contact Info

Product

Resources

About